This is a Phase 3, randomized, observer-blind study in healthy individuals.
The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate (BNT162b2):
As a 30-microgram dose, administered from 1 of 4 manufacturing lots (batches)
As a 20-microgram dose, administered from 1 of the manufacturing lots
As a 2-dose (separated by 21 days) schedule
In people 12 through 50 years of age